Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-23

Clinical Trial Update: A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream" [Phase 3]

View source ↗

Summary

Phase 3 clinical endpoint bioequivalence study of Oxymetazoline Hydrochloride Cream completed for rosacea; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxymetazoline Hydrochloride Cream (oxymetazoline)

Snippet

Sponsor: Actavis Inc. | Conditions: Rosacea | Phase 3 | Status: COMPLETED | Results posted: 2021-06-23